Antipsychotic Medications: First and Second Generation Reference

Antipsychotic medications are a class of psychotropic agents prescribed primarily to treat conditions involving psychosis, including schizophrenia, bipolar disorder with psychotic features, and treatment-resistant depression. This reference page covers the two major pharmacological generations of antipsychotics — first-generation (typical) and second-generation (atypical) — their mechanisms of action, clinical applications, and the regulatory and safety frameworks governing their use. Understanding the structural differences between these generations has direct bearing on prescribing patterns, patient monitoring requirements, and risk classification under U.S. Food and Drug Administration (FDA) labeling standards.

Definition and scope

Antipsychotic medications fall under the broader classification of psychiatric pharmacotherapies described in the psychiatric medication classes reference framework. The FDA divides approved antipsychotics into two broad generations based on receptor binding profiles and the historical period of their clinical introduction.

First-generation antipsychotics (FGAs), also called typical antipsychotics, include agents such as haloperidol, chlorpromazine, fluphenazine, and thioridazine. These were introduced beginning in the 1950s and work predominantly through dopamine D2 receptor antagonism in the mesolimbic pathway. The FGA class is further subdivided by potency:

1. High-potency FGAs (e.g., haloperidol, fluphenazine) — lower sedation risk, higher extrapyramidal symptom (EPS) risk
2. Mid-potency FGAs (e.g., perphenazine, loxapine) — intermediate profile
3. Low-potency FGAs (e.g., chlorpromazine, thioridazine) — higher sedation, anticholinergic burden, lower EPS risk

Second-generation antipsychotics (SGAs), or atypical antipsychotics, emerged from the 1990s onward and include clozapine, olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, lurasidone, and paliperidone. SGAs combine D2 antagonism with serotonin 5-HT2A receptor antagonism, a mechanism that is associated with a reduced EPS burden relative to FGAs (FDA Drug Safety Communications).

The FDA's Orange Book and individual drug labeling documents are the authoritative sources for approved indications, which vary considerably by agent within each generation.

How it works

The core pharmacological distinction between FGAs and SGAs lies in receptor selectivity and binding affinity ratios.

FGAs achieve therapeutic effect primarily by blocking dopamine D2 receptors across four dopaminergic pathways. Blockade in the mesolimbic pathway reduces positive psychotic symptoms (hallucinations, delusions). Blockade in the nigrostriatal pathway, however, produces the extrapyramidal side effects — including akathisia, dystonia, drug-induced parkinsonism, and, with prolonged use, tardive dyskinesia — for which FGAs carry a class-level FDA black box warning. Blockade in the tuberoinfundibular pathway elevates prolactin, producing hyperprolactinemia.

SGAs maintain D2 antagonism but incorporate high-affinity 5-HT2A antagonism. This serotonin-dopamine balance, described in the pharmacology literature as the SDA (serotonin-dopamine antagonist) mechanism, is theorized to preferentially reduce mesolimbic D2 activity while partially sparing nigrostriatal pathways. The result is a lower, though not absent, EPS risk. Clozapine, the first approved SGA and still the only FDA-approved agent for treatment-resistant schizophrenia, additionally carries a black box warning for agranulocytosis, requiring enrollment in the Clozapine REMS (Risk Evaluation and Mitigation Strategy) program administered by the FDA (FDA REMS Program).

SGAs as a class carry FDA black box warnings for increased mortality in elderly patients with dementia-related psychosis — a warning that also applies to FGAs — based on post-marketing data reviewed by the FDA's Office of Drug Evaluation.

Metabolic effects represent a key distinction favoring FGAs in specific populations. Olanzapine and clozapine in particular are associated with significant weight gain, dyslipidemia, and elevated diabetes risk, documented in the American Diabetes Association and American Psychiatric Association 2004 consensus statement on antipsychotics and metabolic risk.

Common scenarios

Antipsychotic prescribing occurs across a range of clinical presentations. The following represents the primary documented indications by agent class:

1. Schizophrenia and schizoaffective disorder — The most established indication for both generations. The National Institute of Mental Health (NIMH) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, published in the New England Journal of Medicine in 2005, compared FGA perphenazine directly against four SGAs across 1,493 patients with schizophrenia, finding no statistically significant efficacy advantage for SGAs over the FGA comparator on the primary outcome measure of treatment discontinuation. More information on schizophrenia-specific treatment contexts appears in the schizophrenia and psychotic disorders reference.

2. Bipolar disorder — Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone carry FDA-approved indications for bipolar mania or bipolar depression. The bipolar disorder diagnosis and care reference addresses the broader treatment framework within which antipsychotics are deployed alongside mood stabilizers.

3. Major depressive disorder with psychotic features — Low-dose FGAs and adjunctive SGAs (aripiprazole, quetiapine, brexpiprazole) are used in treatment-resistant or psychotic depression. See the depression and mood disorders page for condition context.

4. Acute agitation in inpatient settings — FGAs (particularly haloperidol) and IM formulations of SGAs (olanzapine, ziprasidone) are used in emergency psychiatric settings under protocols governed by The Joint Commission's hospital accreditation standards.

5. Tourette syndrome and severe behavioral disturbances in developmental disorders — Haloperidol and risperidone carry FDA labeling for Tourette syndrome. Risperidone and aripiprazole have FDA-approved indications for irritability associated with autistic disorder.

Decision boundaries

The clinical and regulatory factors that distinguish FGA versus SGA selection center on three axes: side effect profile tolerance, route of administration, and specific FDA-approved indication.

Key structural differences for reference:

Regulatory monitoring requirements differ by agent. Clozapine mandates absolute neutrophil count (ANC) monitoring at defined intervals per the FDA REMS program. SGAs with significant metabolic liability require baseline and periodic metabolic panels, per American Psychiatric Association (APA) Practice Guidelines. Tardive dyskinesia monitoring for FGAs follows the Abnormal Involuntary Movement Scale (AIMS) protocol, a structured assessment instrument widely referenced in psychiatric training standards.

Long-acting injectable formulations exist within both generations and are indicated where oral medication adherence is a documented clinical concern — a consideration specifically addressed in the inpatient psychiatric care explained reference and relevant to transitions from acute settings.

The FDA's MedWatch program is the designated reporting pathway for adverse events associated with any FDA-approved antipsychotic (FDA MedWatch).

References

• U.S. Food and Drug Administration — Drug Safety Communications
• FDA REMS Program (Clozapine)
• FDA MedWatch Adverse Event Reporting
• National Institute of Mental Health (NIMH) — CATIE Schizophrenia Study
• American Psychiatric Association (APA) Practice Guidelines
• FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
• The Joint Commission — Hospital Accreditation Standards